[Paclitaxel versus doxorubicin in first-line therapy of metastatic breast carcinoma].
Tanner
J
J
Kuhnt
T
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D015996:Survival Rate
D000970:Antineoplastic Agents; D004317:Doxorubicin; D017239:Paclitaxel